Seagen Inc (SGEN)

[shub]

CD: Took a nibble of AMFE but it does look quite risky.
Not quite as risky and also growing fast is NVTA.
PACB is interesting, if less exciting.
IONS is sorta like SGEN in prospects.
A conservative investor would touch none of them...grin.

[shub]

Thanks C Daniel:
I'll give AMFE a good gander.

[cdaniel394]

Thank you. Just had a friends brother who worked there at the time. Pure luck.

[shub]

With all their drugs in testing or trials, a big pipeline, and the first of them FDA approved, the technology proved valid...It's reasonable to hope that SGEN will pay for your whole house quite nicely.
(Good attitude , huh).

[cdaniel394]

Also, I don't know your risk tolerance, but I've been doing quite well in Amfil Technologies- AMFE. Should break out big time in the next few weeks. Good luck!

[cdaniel394]

Quite all right. Been in SGEN since the $4.00 range. It's on cruise control for me and haven't been watching the daily developments. Going to use this for a down payment on a house for when I retire in a few years.

[shub]

Sorry, wasn't paying attention to the time line, as usual.

[cdaniel394]

Easy to make that call when hindsight is 20/20.

[shub]

nope,
"Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS(R) (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma"
Daniel, check out the stock news before asking please.
Hodgkins is a rather popular disease with very serious consequences and the treatments have had nasty side effects.

[cdaniel394]

This up big on take over speculation?

[shub]

Taking a beating on a week of mixed news.
We bowed out of 1 phase 3 trial and look good for acceptance by the FDA on another. Those last results weren't scintillating, but beats the SOC.
And there's a whole big pipeline marching up behind those.

[shub]

Prescient purchase North...$36 for me.
Credit to you...Hope you've done as well on your other holdings.

[north40000]

Nicely above our purchase price[basis] many years ago too---> $6.30.

[shub]

Thanks North.
I went wallowing around their web site and didn't see reference to it either.
Still nicely above my purchase price on this one and it seems like a decent bet.
Having lost some friends to blood cancers, with another one fading, it's an effort worth backing.
Sometimes the FDA's clinical holds don't make much sense and they can linger inexplicably long.

[north40000]

The post you replied to was made a month ago and the shares have traded + since. Is the particular clinical trial still on hold? I doubt it, but have not looked.

[shub]

Our main product is not free of possible nasty side effects...It's the nature of the beast. We poison both you and your cancer and try to trim it so you survive and the cancer doesn't. It tends to be a fine line. The alternative tends to be death.
Clinical holds come with the territory.

[north40000]

Clinical hold on a SGEN trial...PM trading shares trading ~ $9.80 down to $52.

[shub]

Up 15% on Ph3 trial enlistment filled.

[stocktrademan]

SGEN bullish 55.18

pennant



normal chart


log chart

[TREND1]

SGEN H D W

[TREND1]

SGEN DAY

[trendmkr]

Delving Into Seattle Genetics’s Upcoming Readout http://marketexclusive.com/delving-seattle-genetics-inc-nasdaqsgens-upcoming-readout/9758/?icd1

[Mitshu35]

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
BY PR Newswire — 2:30 AM ET 06/11/2016

COPENHAGEN, Denmark, June 11, 2016 /PRNewswire/ -- Seattle Genetics, Inc. today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' ( SGEN ) newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations.
Seattle Genetics, Inc.

Based on data from the ongoing phase 1 clinical trial, a phase 3 clinical trial, called CASCADE, was recently initiated evaluating 33A in combination with HMAs in previously untreated AML patients not candidates for intensive induction chemotherapy. Seattle Genetics (SGEN) is also evaluating 33A broadly across multiple lines of therapy in patients with myeloid malignancies, including ongoing and planned phase 1 and 2 clinical trials for newly diagnosed or relapsed AML and for previously untreated myelodysplastic syndrome (MDS). More information about 33A and ongoing clinical trials can be found at www.ADC-CD33.com.
"Hypomethylating agents, or HMAs, are the current standard of care for AML patients who are not able to tolerate intensive therapy. HMAs have limited benefit, with low response rates and median overall survival of 10 months or less," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics (SGEN). "We believe that adding 33A to HMAs may improve efficacy and has the potential to redefine the treatment of AML. The clinical data at ASH showing high response rate, manageable tolerability profile and low early mortality reported have been maintained in this larger data set, and support our recently initiated phase 3 CASCADE clinical trial, which is now enrolling patients."

"There is a dire need to improve outcomes for patients with AML," said Amir Fathi, M.D., investigator of the phase 1 trial who will present the data at EHA. "The anti-leukemic activity we have observed in the phase 1 clinical trial evaluating 33A combination therapy in AML patients continues to be encouraging. This is an incredibly difficult disease to treat and the results to-date continue to show a balance of activity and tolerability together with low early mortality rates. The data presented suggest that the addition of 33A improves the rates of response and durable remissions in comparison to that seen historically from using the current standard of care alone."

SGN-CD33A in Combination with Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Older Patients with AML (Abstract #S503, oral presentation on Saturday, June 11, 2016 at 4:30 p.m. CEST)

Outcomes for AML patients who are not candidates for intensive chemotherapy or allogeneic stem cell transplant are dismal. Low intensity treatment options, including HMAs (azacitidine and decitabine), are limited. Interim results from the first 25 patients in the ongoing phase 1 study evaluating 33A in combination with HMAs in frontline AML were presented at the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition. Updated interim results from the ongoing phase 1 study were presented in an oral session at EHA.
Data were reported from 53 frontline unfit AML patients with a median age of 75 years and intermediate or adverse cytogenetic risk who had declined intensive therapy. Forty-five percent of patients had evidence of underlying myelodysplasia. Key findings presented by Dr. Fathi include:
Of 49 efficacy-evaluable patients treated with 33A combined with either azacitidine or decitabine, the overall response rate was 76 percent. Complete remission (CR) or complete remission with incomplete platelet or neutrophil recovery (CRi) was observed in 35 patients (71 percent). The remission rate (CR+CRi) was similar between the two 33A and HMA combination treatment groups (71 percent combined with azacitidine and 72 percent combined with decitabine).

Responses were observed in higher-risk patients, with remissions achieved in 16 of 22 patients (73 percent) with underlying myelodysplasia and 15 of 18 patients (83 percent) with adverse cytogenetics.

Patients who achieved minimal residual disease included eight of 19 (42 percent) CR patients and five of 15 (33 percent) CRi patients.
The median overall survival for all patients in the phase 1 trial is interim and expected to evolve. The estimated median overall survival for the first 25 patients enrolled in the study was 12.75 months, with a median follow-up of 12.58 months.

Median relapse-free survival was 7.7 months (range, 0.0+ and 11.3+) with 27 patients (51 percent) remaining alive and on study as of last follow-up. The 30- and 60-day mortality rates were two and eight percent, respectively.

The most common treatment-related adverse events of any grade occurring in 20 percent or more of patients were fatigue (57 percent), thrombocytopenia (53 percent), nausea (49 percent), febrile neutropenia (45 percent), and constipation and anemia (42 percent each). The most common Grade 3 or 4 treatment-emergent adverse events occurring in 20 percent or more of patients were febrile neutropenia, thrombocytopenia, neutropenia, anemia and fatigue.

About Acute Myeloid Leukemia

Acute myeloid leukemia, also called acute myelocytic leukemia or AML, is an aggressive type of cancer of the bone marrow and blood that progresses rapidly without treatment. AML is a cancer that starts in the cells that are supposed to mature into different types of blood cells. AML starts in the bone marrow (the interior part of bones, where new blood cells are made) and quickly moves into the blood. According to the American Cancer Society, in 2016 approximately 20,000 new cases of AML (mostly in adults) will be diagnosed and nearly 10,500 deaths will occur from AML (almost all will be in adults).

About Vadastuximab Talirine (SGN-CD33A)

Vadastuximab talirine (SGN-CD33A; 33A) is a novel investigational ADC targeted to CD33 utilizing Seattle Genetics' (SGEN) newest ADC technology. CD33 is expressed on most AML and MDS blast cells. The CD33 antibody is attached to a highly potent DNA binding agent, a pyrrolobenzodiazepine (PBD) dimer, via a proprietary site-specific conjugation technology to a monoclonal antibody with engineered cysteines (EC-mAb). PBD dimers are significantly more potent than systemic chemotherapeutic drugs and the site-specific conjugation technology (EC-mAb) allows uniform drug-loading of the cell-killing PBD agent to the anti-CD33 antibody. The ADC is designed to be stable in the bloodstream and to release its potent DNA binding agent upon internalization into CD33-expressing cells.

33A was granted Orphan Drug Designation by both the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of AML. FDA orphan drug designation is intended to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States.

About Seattle Genetics (SGEN)
Seattle Genetics (SGEN) is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The company's industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab vedotin), the company's lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs approved globally in more than 60 countries for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics (SGEN) is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC in a phase 3 trial for acute myeloid leukemia. Headquartered in Bothell, Washington, Seattle Genetics (SGEN) is also advancing a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

[TREND1]

*****Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, July 26, 2016

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
• Telephone [phone] (domestic) or 719-325-2329 (international); conference ID 2574870
• Webcast available at www.seattlegenetics.com in the Investors and News section

REPLAY access
• Telephone replay will be available beginning at approximately 4:30 p.m. PT on Tuesday, July 26, 2016 through 5:00 p.m. PT on Friday, July 29, 2016 by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference ID 2574870
• Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section

[TREND1]

Short % of Float = 24.5%

[TREND1]

***** SGEN DAY

[TREND1]

Inst % Owned = 99%

[TREND1]

FLOAT=61 MILLION

[TREND1]

EPS=-.93

[TREND1]

*****AML Therapies: Seattle Genetics Vs. GlycoMimetics

ALSO JUNO MENTIONED

Jul. 15, 2016 8:10 AM ET
About: GlycoMimetics (GLYC), SGEN, Includes: JUNO


William Meyers
Follow (1,085 followers)

Long only, tech, biotech, research analyst


Summary


•Acute Myeloid Leukemia is very difficult to treat successfully.

•Seattle Genetics SGN-CD33A started a Phase 3 trial.

•GlycoMimetics GMI-1271 started Phase 2 trial.

•There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.



http://seekingalpha.com/article/3988622-aml-therapies-seattle-genetics-vs-glycomimetics?ifp=0&app=1

[stocktrademan]

$SGEN recent news/filings

bullish

## source: finance.yahoo.com

Mon, 01 Jun 2015 15:44:01 GMT ~ Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in the AETHERA Post-Transplant Consolidation Setting and in Frontline DLBCL at ASCO Annual Meeting

[at noodls] - CHICAGO--(BUSINESS WIRE)--Jun. 1, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced several ADCETRIS (brentuximab vedotin) data presentations in the AETHERA post-transplant consolidation setting ...

read full: http://www.noodls.com/view/8A041653E63633EAED7FC22A1AF995D15F502AD1
*********************************************************

Mon, 01 Jun 2015 14:46:00 GMT ~ 10:46 am Seattle Genetics announces Adcetris data presentations, in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma, and in frontline diffuse large B-cell lymphoma


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#sgen
*********************************************************

Mon, 01 Jun 2015 14:45:00 GMT ~ Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in the AETHERA Post-Transplant Consolidation Setting and in Frontline DLBCL at ASCO Annual Meeting

[Business Wire] - Seattle Genetics, Inc. today announced several ADCETRIS data presentations in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma and in frontline diffuse large B-cell lymphoma at the American Society of Clinical Oncology 50th Annual Meeting being held May 29 to June 2, 2015, in Chicago, IL.

read full: http://finance.yahoo.com/news/seattle-genetics-highlights-adcetris-brentuximab-144500733.html
*********************************************************

Thu, 28 May 2015 13:46:11 GMT ~ Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting

[at noodls] - BOTHELL, Wash.--(BUSINESS WIRE)--May 28, 2015-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be ...

read full: http://www.noodls.com/view/8ADD42EF697AF6435C3F1BFD4DB198DBD36A526B
*********************************************************

Thu, 28 May 2015 13:00:00 GMT ~ Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting

[Business Wire] - Seattle Genetics, Inc. today announced that data from multiple proprietary and collaborator antibody-drug conjugate programs will be highlighted in more than 10 sessions at the American Society of Clinical Oncology 2015 Annual Meeting being held May 29 to June 2, 2015 in Chicago, IL.

read full: http://finance.yahoo.com/news/seattle-genetics-announces-clinical-data-130000628.html
*********************************************************

$SGEN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SGEN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SGEN/company-info
Ticker: $SGEN
OTC Market Place: Not Available
CIK code: 0001060736
Company name: Seattle Genetics, Inc.
Company website: http://www.seattlegenetics.com
Incorporated In: DE, USA

$SGEN share structure

## source: otcmarkets.com

Market Value: $5,418,840,899 a/o Jun 01, 2015
Shares Outstanding: 124,886,861 a/o Apr 28, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$SGEN extra dd links

Company name: Seattle Genetics, Inc.
Company website: http://www.seattlegenetics.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SGEN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SGEN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SGEN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SGEN/news - http://finance.yahoo.com/q/h?s=SGEN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SGEN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SGEN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SGEN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SGEN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Seattle+Genetics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Seattle+Genetics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Seattle+Genetics%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.seattlegenetics.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.seattlegenetics.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.seattlegenetics.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SGEN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001060736&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SGEN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SGEN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SGEN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SGEN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SGEN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SGEN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SGEN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SGEN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SGEN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SGEN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SGEN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SGEN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SGEN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SGEN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SGEN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SGEN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SGEN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SGEN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SGEN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SGEN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SGEN



$SGEN DD Notes ~ http://www.ddnotesmaker.com/SGEN

[FutureMeDead]

$SGEN Intraday Elliott Wave Analysis 03/16/15 (VIDEO)

http://futuremedead.com/?p=1040

[chef911]

Burning down the house against a weak tape.

[maytepper]

Seattle Genetics: Continued Quality And Breadth Of Data Should Yield Investor Re-Engagement, Says HC Wainwright http://www.smarteranalyst.com/2014/12/09/seattle-genetics-continued-quality-and-breadth-of-data-should-yield-investor-re-engagement-says-h-c-wainwright/

[InvestmentFan]

Wow, that's very interesting. Thank you for providing the link.

[north40000]

https://ash.confex.com/ash/2014/webprogram/Paper67048.html

[DewDiligence]

Good data, dumb CC:

#msg-106719272
#msg-106719901

[north40000]

http://ih.advfn.com/p.php?pid=nmona&article=63542299

>>>
Additional collaboration combines Genmab’s proprietary antibodies and Seattle Genetics’ ADC technology
New ADC program will target AXL expressed on multiple tumor types

Seattle Genetics, Inc. (Nasdaq: SGEN) and Genmab A/S (OMX: GEN) today announced that the companies have entered into an additional antibody-drug conjugate (ADC) collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive rights to utilize Seattle Genetics’ auristatin-based ADC technology with Genmab’s HuMax®-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers. Seattle Genetics is also entitled to receive more than $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of any resulting products. In addition, prior to Genmab’s initiation of a Phase III study for any resulting products, Seattle Genetics has the right to exercise an option to increase the royalties to double digits in exchange for a reduction of the milestone payments owed by Genmab. Irrespective of any exercise of option, Genmab remains in full control of development and commercialization.

“This collaboration with Genmab further extends the reach of our industry-leading ADC technology for use with novel oncology targets, while providing us with a compelling financial value proposition as the program advances,” said Natasha Hernday, Vice President, Corporate Development at Seattle Genetics. “Genmab’s impressive track record in the development of antibody-based therapies for the treatment of cancer, including an ADC in a Phase I clinical trial for solid tumors utilizing Seattle Genetics technology from our first agreement, make them a strong partner for this new collaboration.”

“This new collaboration with Seattle Genetics adds another ADC program to our innovative pre-clinical pipeline of antibodies developed using the latest technological advances in cancer therapeutics. Pre-clinical work identified AXL as an excellent target for an ADC therapeutic approach,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “Accessing state-of-the art technology of companies such as Seattle Genetics who are experts in their field provides another means for Genmab to develop differentiated cancer therapeutics while retaining maximal ownership of our therapeutic products.”

Seattle Genetics and Genmab entered into an ADC collaboration for HuMax-TF-ADC in September 2010. HuMax-TF-ADC, targeting the Tissue Factor antigen, is in a Phase I trial for solid tumors. Seattle Genetics has the right to exercise a co-development option to share all future costs and profits for HuMax-TF-ADC at the end of Phase I.

Today's news will not impact Genmab's 2014 financial guidance.

About HuMax-AXL-ADC

HuMax-AXL-ADC is an antibody-drug conjugate (ADC) combining a high affinity human monoclonal antibody against AXL with Seattle Genetics’ clinically validated cytotoxic drug. AXL is a signaling molecule involved in multiple processes of tumor development and progression. The target molecule is highly expressed on a variety of solid cancers.

About Antibody-Drug Conjugates (ADCs)

ADCs are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells. This approach is intended to spare non-targeted cells and reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. With 15 years of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents, such as monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF) and pyrrolobenzodiazepine (PBD) dimer, and stable linker systems that attach these cytotoxic agents to the antibody. Of the roughly 40 ADCs in clinical development, more than 60 percent utilize Seattle Genetics’ proprietary ADC technology....[more]<<<

[maytepper]

Seattle Genetics: Recent Macro Weakness Has Created A Buying Opportunity, Says H.C. Wainwright http://www.smarteranalyst.com/2014/08/01/seattle-genetics-recent-macro-weakness-has-created-a-buying-opportunity-says-h-c-wainwright/

[RVL]

Falling Knife?
On 06/04/14, FELIX BAKER, reported a net BUY trade of SGEN with a net transaction amount of $9,828,093. Net non-zero shares traded: 281963. See below for more information on Seattle Genetics, with symbol SGEN traded on the NasdaqNM. Original SEC Filing Period of Report: 2014-06-02

[RVL]

Thankfully, I did.
RVL

[RVL]

Thankfully, I did.

[cdaniel394]

Who is going to grab the falling knife first? Didn't see this coming two weeks ago.

[KICK1]

I'm interested in #SGEN

[buccaneer1961]

http://www.insidermonkey.com/blog/baker-bros-strengthens-position-in-seattle-genetics-inc-sgen-305463/

[surf1944]

8:32AM Seattle Genetics highlights ADCETRIS Phase 2 Clinical data in diffuse large B-cell lymphoma; 42% objective response rate in relapsed or refractory DLBCL (SGEN) 41.16 : Co announces updated results from a phase 2 clinical trial of ADCETRIS in diffuse large B-cell lymphoma and other B-cell non-Hodgkin lymphomas. ADCETRIS is an antibody-drug conjugate directed to CD30. ADCETRIS is currently not approved for the treatment of DLBCL or other B-cell lymphomas.

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL and Other B-cell Lymphomas
Interim data from an ongoing phase 2 clinical trial were reported from 50 patients with DLBCL and 18 patients with other B-cell lymphomas. Among the DLBCL patients, the median age was 63 years, 74% were refractory to frontline therapy and 82% were refractory to their most recent prior therapy. Patients were treated with single-agent ADCETRIS every three weeks. The trial was designed to assess the antitumor activity, duration of response and safety profile of ADCETRIS in these patients.
Key findings presented included:

Of the 50 patients with DLBCL, 42% achieved an objective response, including 16% complete remissions and 26% partial remissions.
At the time of data analysis, the median duration of response for DLBCL was 5.8 months. For DLBCL patients who achieved a complete remission, the median duration of response was 11.5 months.
Objective responses were observed across a broad range of CD30 expression, from DLBCL patients with undetectable CD30 by standard immunohistochemistry testing to those with CD30 expression up to 90%.
The most common treatment-emergent adverse events of any grade in patients with DLBCL and other B-cell lymphomas occurring in more than 25% of all patients enrolled were fatigue (49%), neutropenia (40%), nausea (38%), diarrhea (37%) and fever (29%).
The most common Grade 3 treatment-emergent adverse events in patients with DLBCL and other B-cell lymphomas were neutropenia and anemia. The only Grade 4 treatment-emergent event was neutropenia. Serious adverse events considered related to treatment and occurring in more than one patient were pneumonia (three patients) and anemia, febrile neutropenia, neutropenia and thrombocytopenia (two patients each).

[surf1944]

11:32AM Seattle Genetics highlights data from broad ADCETRIS (brentuximab vedotin) development program at ASH 2013 (SGEN) 41.65 -2.70 : Co summarized ADCETRIS (brentuximab vedotin) data in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma from multiple presentations at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013. Highlights include encouraging interim data from a phase 2 clinical trial evaluating ADCETRIS as a single-agent for previously untreated HL patients age 60 or older and updated data from a phase 1 clinical trial of ADCETRIS in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma (MTCL) patients, commonly referred to as peripheral T-cell lymphoma (PTCL). In addition, data were presented from an investigator-sponsored phase 2 clinical trial evaluating ADCETRIS in relapsed cutaneous T-cell lymphoma (CTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is currently not approved for the treatment of frontline HL, frontline MTCL or relapsed CTCL.

[pete7]

We're going to see a big run any time now

[surf1944]

9:02AM Seattle Genetics to present clinical data from broad ADCETRIS development program and novel antibody-drug conjugate sgn-cd19a at ash 2013; data support goal to establish adcetris as the foundation of therapy for cd30-positive malignancies (SGEN) 38.92 : Co announced that multiple abstracts will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013, highlighting the following:


Clinical data for ADCETRIS (brentuximab vedotin) in CD30-positive lymphomas, including Hodgkin lymphoma (HL), mature T-cell lymphoma (MTCL), cutaneous T-cell lymphoma (CTCL) and diffuse B-cell lymphoma (DLBCL)
Interim phase 1 clinical data for SGN-CD19A, a novel antibody-drug conjugate (ADC), in acute lymphoblastic leukemia (ALL)
Final phase 1 data from two ADC candidates that utilize Seattle Genetics' proprietary technology being developed by Genentech, a member of the Roche Group (SIC: RO, ROG; OTCQX: RHHBY), including an anti-CD22 ADC (pinatuzumab vedotin, RG7593) and an anti-CD79b ADC (polatuzumab vedotin, RG7596).

SGN-CD19A is an ADC targeting CD19, a protein expressed broadly on B-cell malignancies. Preclinical data presented at the 2011 American Association for Cancer Research Annual Meeting demonstrated that SGN-CD19A effectively binds to target cells, internalizes and induces potent cell-killing activity and durable tumor regressions at low doses in multiple cancer models. SGN-CD19A is being evaluated in two ongoing phase 1 clinical trials for patients with B-cell ALL and aggressive non-Hodgkin lymphoma (NHL).

[surf1944]

9:02AM Seattle Genetics highlights ADCETRIS (Brentuximab Vedotin) clinical data in the frontline setting at the International Symposium on Hodgkin Lymphoma; data frm ADCETRIS Phase 1 Frontline Hodgkin Lymphoma clinical trial support enrollment of ongoing global phase 3 ECHELON-1 clinical trial for patients with advanced frontline HL (SGEN) 40.70 : Co highlighted multiple ADCETRIS (brentuximab vedotin) data presentations at the 9th International Symposium on Hodgkin Lymphoma (ISHL) being held October 12-15, 2013 in Cologne, Germany. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in August 2011 for relapsed HL and sALCL and conditional marketing authorization by the European Commission in October 2012 for relapsed or refractory HL and sALCL.

Three oral and nine poster presentations at ISHL illustrate the broad clinical development program for ADCETRIS in HL, including data from a phase 1 frontline advanced HL trial and a poster presentation describing the ongoing global phase 3 ECHELON-1 clinical trial in frontline HL. ADCETRIS is currently not approved for use in the treatment of newly diagnosed HL